Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in failure to maintain clinical or endoscopic remission compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).
1 finding from 1 review
Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in exclusion/withdrawal after entry compared with comparator 5‐aminosalicylic acid formulation (moderate certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid leads to lower failure to maintain clinical or endoscopic remission compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in withdrawal due to adverse event compared with sulfasalazine (moderate certainty).
1 finding from 1 review
Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid probably leads to higher exclusion/withdrawal after entry compared with sulfasalazine (moderate certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in withdrawal due to adverse event compared with placebo (moderate certainty).
1 finding from 1 review
Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in exclusion/withdrawal after entry compared with placebo (moderate certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid leads to higher failure to maintain clinical or endoscopic remission compared with sulfasalazine (high certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with sulfasalazine (moderate certainty).
1 finding from 1 review
Remission · people with active UC
Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) may leads to higher remission compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
Disease improvement · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found